临床试验/PER-079-02

PER-079-02已完成1 期

PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF THE COMBINED TREATMENT OF BMS-188667 PLUS METOTREXATE VERSUS METOTREXATE ONLY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE METOTREXATE RESPONSE.

BRISTOL MYERS SQUIBB COMPANY,0 个研究点目标入组 0 人开始时间: 2002年12月12日最近更新: 2023年9月4日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: BRISTOL MYERS SQUIBB COMPANY,

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 0（—）

入选标准

•Rheumatoid Arthritis (RA) for greater than 1 year from the time of initial diagnosis of RA.
•Participants must have been taking methotrexate for at least 3 months with at least a weekly dose of 15 mg.

排除标准

•Women who are pregnant or nursing.
•Women who have obtained a positive result in the pregnancy test performed during the enrollment or before the administration of the study drug.
•Women of childbearing age who are unwilling or unable to use a
•method of birth control that is acceptable throughout the study and during a
•period of up to 10 weeks after the last infusion of the study medication.

研究者

发起方

BRISTOL MYERS SQUIBB COMPANY,

相似试验

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

PER-076-06GLAXOSMITHKLINE PERU S.A.,

PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED WITH PLACEBO CLINICAL STUDY THAT COMPARES GW572016 AND LETROZOLE VERSUS LETROZOLE IN PATIENTS WITH BREAST CANCER OF METASTATIC OR ADVANCED FOR THE RECEPTOR OF ESTROGEN / PROGESTERONE-C509 Breast, unspecifiedBreast, unspecifiedC509

PER-064-04GLAXOSMITHKLINE PERU S.A.,36

进行中（未招募）

PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ADULT-ONSET ACTIVE AND PROGRESSIVE PSORIATIC ARTHRITIS (PSA) - NDMedDRA version: 9.1Level: LLTClassification code 10037160Psoriatic arthritis

EUCTR2009-011720-59-ITSchwarz Biosciences, GmbH500

进行中（未招募）

EUCTR2009-011719-19-DECB BioSciences GmbH600

进行中（未招募）

PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXIAL SPA)axial spondyloarthritis (axial SpA)MedDRA version: 12.1Level: LLTClassification code 10002557Term: Ankylosing spondylitis and other inflammatory spondylopathiesMedDRA version: 12.1Level: LLTClassification code 10051265Term: Spondyloarthropathy

EUCTR2009-011719-19-FRSCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies500